Acute management pertains to the urgent and immediate treatments administered during an asthma exacerbation.
Pharmacological treatments are critical and are categorized in a detailed manner in asthma management protocols.
Albuterol Administration
Albuterol: The primary medication utilized for acute treatment.
Can be delivered via:
SVN (Small Volume Nebulizer)
HHN (Handheld Nebulizer)
Administered mixed with normal saline solution.
Typical dosage for continuous beta-2 agonist therapy:
Dosage Range: 5 to 20 milligrams per hour.
It is more commonly closer to 20 mg/hour than 5 mg/hour, influenced by the patient's age.
Mechanism of Action
Continuous administration of Albuterol leads to:
Downregulation of beta-2 receptors:
This refers to the decreased number and affinity of beta-2 receptors, leading to reduced receptor effectiveness over time.
Increased Secretions:
Binding of SABA (Short-Acting Beta Agonist) like Albuterol stimulates submucosal glands to increase mucus secretions.
Albuterol acts as a segregogue, which promotes secretory activity.
Side Effects of Albuterol Treatment
Decreased Potassium:
Albuterol can drive potassium into cells, resulting in lower serum potassium levels.
Clinical Implication:
Albuterol may be utilized in cases of hyperkalemia (high potassium), which can lead to severe cardiac complications.
Increased Glucose Levels:
Patients with diabetes receiving multiple doses of Albuterol need careful monitoring of glucose levels due to the risk of increased blood glucose.
Increased Heart Rate:
Use of Albuterol can lead to tachycardia; continuous cardiac monitoring is essential during treatment with continuous Albuterol.
Combination Therapy
Ipratropium Bromide:
Considered a short-acting muscarinic antagonist (SAMA) and often used in conjunction with Albuterol.
Typical dosage: 0.5 mg in normal saline solution administered every 4 to 6 hours.
Common practice: Include it in the initial one or two treatments to enhance therapeutic efficacy.
Special Populations
The management strategies discussed may require adaptations for specific populations or clinical scenarios, although explicit details on special populations were not provided in this segment of the transcript.